세계의 면역 레퍼토리 시퀀싱 시장 예측(-2030년) : 제품별, 기술별, 워크플로우별, 용도별, 최종사용자별, 지역별

The global IRS market is projected to reach USD 565 million in 2030 from USD 334 million in 2025, growing at a CAGR of 9.6% during the forecast period. This market is growing as increased technological advancements continue to enhance the efficiency, sensitivity, and scalability of immunoassay-based research solutions. Innovations such as NGS integration, automated liquid handling systems, and high-throughput screening platforms enable faster and more accurate assay results. These advancements streamline workflows, reduce manual errors, and increase throughput, making IRS technologies more accessible and reliable for research and clinical applications. Moreover, the growing focus on personalized and precision medicine drives the demand for IRS solutions, as healthcare providers and researchers increasingly require tools that detect specific biomarkers and tailor treatments to individual patients. This shift toward targeted therapies fosters the development of particular assay kits & reagents designed to support companion diagnostics, therapeutic monitoring, and individualized treatment strategies. As a result, there is a rising need for immunoassay technologies that can deliver accurate, patient-centric data to guide clinical decisions and improve outcomes.

The sequencing technology segment held the largest share in the immune repertoire sequencing products market, by technology, during the forecast period.

In 2024, sequencing technology held the largest market within the IRS products market by technology. Sequencing technologies are the core enablers of immune repertoire sequencing studies. Advances in NGS technologies have significantly lowered the cost per run while improving read lengths, throughput, and turnaround time-making sequencing more scalable and accessible across clinical and research settings. Moreover, the continuous innovation in platform technologies by key industry players has led to the commercialization of highly efficient, user-friendly sequencers that support a broad array of applications, including immuno-oncology, infectious disease profiling, and vaccine development. Thus, this central role, coupled with high adoption rates in both academic and commercial research environments, positions sequencing technology as the largest in the IRS product market.

Academic & research institutes held the largest market share in the immune repertoire sequencing products market, by end user, during the forecast period.

Academic & research institutes are the largest end users of IRS products, such as assay kits & reagents, instruments, and software. Universities and academic medical centers conduct many exploratory and hypothesis-driven studies that rely heavily on IRS technologies for immune profiling, biomarker discovery, and understanding disease mechanisms. The demand for assay kits, reagents, sequencing instruments, and bioinformatics software is consistently high in academia, where diverse research programs require flexible, scalable, and precise tools. Moreover, increased government and institutional funding for immunology, oncology, and infectious disease research further supports the widespread adoption of IRS technologies in academic settings.

The Asia Pacific is expected to be the fastest growing region in the immune repertoire sequencing market during the study period.

The Asia Pacific IRS market is projected to register the highest growth rate during the forecast period. This high growth is attributed to the growing emphasis on healthcare infrastructure development and increased investments in biomedical research. Governments across countries such as China, India, South Korea, and Japan allocate substantial funding to support life sciences and precision medicine initiatives, including the IRS. Additionally, increasing investments of key regional players, considering the enormous growth potential mainly due to the diverse population and low operational costs, is another key factor supporting the region's fastest growth during the forecast period.

The primary interviews conducted for this report can be categorized as follows:

• By Company Type: Tier 1-44%, Tier 2-32%, and Tier 3-24%
• By Designation: (Managers)-45%, (CXOs, Directors)-30%, and (Executives)-25%
• By Region: North America-40%, Europe-25%, Asia-Pacific-20%, Rest of the World-15%

List of Companies Profiled in the Report:

• Illumina, Inc. (US)
• Thermo Fisher Scientific Inc. (US)
• PacBio (US)
• Oxford Nanopore Technologies PLC (UK)
• 10X Genomics (US)
• QIAGEN (Netherlands)
• Agilent Technologies (US)
• Danaher Corporation (US)
• Takara Bio Inc. (Japan)
• Adaptive Biotechnologies (US)
• BGI Group (China)
• Tecan Trading AG (Switzerland)
• Azenta US Inc. (US)
• Personalis, Inc. (US)
• Creative Biolabs (US)
• Celemics, Inc. (South Korea)
• CellCarta (Canada)
• iRepertoire, Inc. (US)
• New England Biolabs (US)
• Cerba Research (Belgium)
• CeGat GmbH (Germany)
• Element Biosciences (US)
• Seqalis (Belgium)
• Synbio Technologies (China)
• MedGenome (US)
• Enpicom (Netherlands)

Research Coverage:

This report provides a detailed picture of the global IRS market. It aims to estimate the market's size and future growth potential across different segments such as the product, service, application product-technology, product-end user, service-end user, and region. The report's scope covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the IRS market. A thorough analysis of the key industry players has provided insights into their business overview, solutions, services, key strategies, partnerships, agreements, new product and service launches, mergers and acquisitions, and recent developments associated with the immune repertoire sequencing market. This report covers the competitive analysis of upcoming startups in the immune repertoire sequencing market ecosystem.

Reasons to Buy this Report :

The report will help market leaders and new entrants with information on the closest approximations of the revenue numbers for the overall immune repertoire sequencing market and its subsegments. It will also help stakeholders understand the competitive landscape and gain more insights to position their businesses better and plan suitable go-to-market strategies. The report also helps stakeholders understand the market pulse and provides information on key market drivers, restraints, challenges, and opportunities.

The report provides insights on the following pointers:

• Analysis of key drivers (Increasing technological advancements, growing focus on precision/personalized medicines, increasing use of IRS in organ transplantation), restraints (need for high capital investments), opportunities (integration of AI and ML in IRS), and challenges (variations in regulatory frameworks and international trade dynamics) influencing the growth of the immune repertoire sequencing market.
• Product/ Service Development/Innovation: Detailed insights on upcoming technologies and new product and service launches in the immune repertoire sequencing market
• Market Development: Comprehensive information about lucrative markets - the report analyses the immune repertoire sequencing market across varied regions.
• Market Diversification: Exhaustive information about new products and services, untapped geographies, recent developments, and investments in the immune repertoire sequencing market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and product and service offerings of leading players in the immune repertoire sequencing market.

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 SEGMENTS CONSIDERED & GEOGRAPHICAL SPREAD
  • 1.3.2 INCLUSIONS & EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS

2 RESEARCH METHODOLOGY

• 2.1 RESEARCH DATA
  • 2.1.1 SECONDARY DATA
    • 2.1.1.1 Key objectives of secondary research
  • 2.1.2 PRIMARY DATA
    • 2.1.2.1 Breakdown of primaries
    • 2.1.2.2 Key objectives of primary research
• 2.2 MARKET ESTIMATION METHODOLOGY
  • 2.2.1 GLOBAL MARKET ESTIMATION
    • 2.2.1.1 Bottom-up approach
    • 2.2.1.2 Insights from primary experts
  • 2.2.2 SEGMENTAL MARKET ESTIMATION (TOP-DOWN APPROACH)
• 2.3 MARKET GROWTH RATE PROJECTION
• 2.4 DATA TRIANGULATION
• 2.5 STUDY ASSUMPTIONS
• 2.6 RESEARCH LIMITATIONS
• 2.7 RISK ANALYSIS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

• 4.1 IMMUNE REPERTOIRE SEQUENCING MARKET OVERVIEW
• 4.2 NORTH AMERICA: IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT AND COUNTRY
• 4.3 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET SHARE, BY TECHNOLOGY, 2025 VS. 2030
• 4.4 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET SHARE, BY END USER, 2025
• 4.5 IMMUNE REPERTOIRE SEQUENCING MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

5 MARKET OVERVIEW

• 5.1 INTRODUCTION
• 5.2 MARKET DYNAMICS
  • 5.2.1 DRIVERS
    • 5.2.1.1 Increasing technological advancements
    • 5.2.1.2 Growing focus on personalized/precision medicines
    • 5.2.1.3 Increasing use of immune repertoire sequencing in organ transplant monitoring
    • 5.2.1.4 Increasing applications in autoimmune disease research
    • 5.2.1.5 Rising focus on cancer immunotherapy research
  • 5.2.2 RESTRAINTS
    • 5.2.2.1 Need for high capital investments
    • 5.2.2.2 Limited clinical adoption and validation
  • 5.2.3 OPPORTUNITIES
    • 5.2.3.1 Integration of AI and ML into immune repertoire sequencing
    • 5.2.3.2 Increasing applications in vaccine development
  • 5.2.4 CHALLENGES
    • 5.2.4.1 Variations in regulatory frameworks and international trade dynamics
    • 5.2.4.2 Lack of workflow and data standardization
• 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.4 PRICING ANALYSIS
  • 5.4.1 AVERAGE SELLING PRICE TREND OF IMMUNE REPERTOIRE SEQUENCING PRODUCTS, BY KEY PLAYER, 2022-2024
  • 5.4.2 AVERAGE SELLING PRICE OF IMMUNE REPERTOIRE SEQUENCING INSTRUMENTS, BY REGION, 2024
• 5.5 SUPPLY CHAIN ANALYSIS
• 5.6 VALUE CHAIN ANALYSIS
• 5.7 ECOSYSTEM ANALYSIS
  • 5.7.1 ROLE IN ECOSYSTEM
    • 5.7.1.1 Product providers
    • 5.7.1.2 Service providers
    • 5.7.1.3 End users
    • 5.7.1.4 Regulatory bodies
• 5.8 TECHNOLOGY ANALYSIS
  • 5.8.1 KEY TECHNOLOGIES
    • 5.8.1.1 High-throughput sequencing
    • 5.8.1.2 Nanopore sequencing
    • 5.8.1.3 Single-molecule real-time (SMRT) sequencing
  • 5.8.2 COMPLEMENTARY TECHNOLOGIES
    • 5.8.2.1 Bioinformatics and data analysis platforms
    • 5.8.2.2 Multiplex PCR
    • 5.8.2.3 5'RACE
  • 5.8.3 ADJACENT TECHNOLOGIES
    • 5.8.3.1 Multi-omics integration
    • 5.8.3.2 Spatial genomics and transcriptomics
    • 5.8.3.3 Single-cell sequencing technologies
• 5.9 PATENT ANALYSIS
• 5.10 TRADE DATA ANALYSIS
  • 5.10.1 IMPORT DATA FOR HS CODE 3822, 2020-2024
  • 5.10.2 EXPORT DATA FOR HS CODE 3822, 2020-2024
• 5.11 KEY CONFERENCES & EVENTS, 2025-2026
• 5.12 REGULATORY ANALYSIS
  • 5.12.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 5.12.2 REGULATORY FRAMEWORK
    • 5.12.2.1 North America
      • 5.12.2.1.1 US
      • 5.12.2.1.2 Canada
    • 5.12.2.2 Europe
      • 5.12.2.2.1 UK
    • 5.12.2.3 Asia Pacific
      • 5.12.2.3.1 China
      • 5.12.2.3.2 Japan
      • 5.12.2.3.3 South Korea
      • 5.12.2.3.4 Australia
      • 5.12.2.3.5 India
      • 5.12.2.3.6 Rest of Asia Pacific
• 5.13 PORTER'S FIVE FORCES ANALYSIS
  • 5.13.1 THREAT OF NEW ENTRANTS
  • 5.13.2 THREAT OF SUBSTITUTES
  • 5.13.3 BARGAINING POWER OF BUYERS
  • 5.13.4 BARGAINING POWER OF SUPPLIERS
  • 5.13.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.14 KEY STAKEHOLDERS & BUYING CRITERIA
  • 5.14.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 5.14.2 KEY BUYING CRITERIA
• 5.15 INVESTMENT & FUNDING SCENARIO
• 5.16 IMPACT OF AI/GEN AI ON IMMUNE REPERTOIRE SEQUENCING MARKET

6 IMMUNE REPERTOIRE SEQUENCING MARKET, BY PRODUCT

• 6.1 INTRODUCTION
• 6.2 ASSAY KITS & REAGENTS
  • 6.2.1 TCR KITS
    • 6.2.1.1 Human TCR kits
      • 6.2.1.1.1 Increased demand for high-throughput TCR profiling in oncology and immunotherapy research to fuel market growth
    • 6.2.1.2 Mouse TCR kits
      • 6.2.1.2.1 Rising demand for TCR profiling in preclinical studies and growing need for standardized workflows to drive segment
  • 6.2.2 BCR KITS
    • 6.2.2.1 Human BCR kits
      • 6.2.2.1.1 Increasing demand for high-throughput profiling and rising focus on immunology research to fuel uptake
    • 6.2.2.2 Mouse BCR kits
      • 6.2.2.2.1 High demand for antibody discovery and preclinical research to boost segment growth
  • 6.2.3 OTHER ASSAY KITS & REAGENTS
• 6.3 INSTRUMENTS & SOFTWARE
  • 6.3.1 TECHNOLOGICAL ADVANCEMENTS IN TRANSLATIONAL RESEARCH AND COMPANION DIAGNOSTICS TO AUGMENT MARKET GROWTH

7 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY TECHNOLOGY

• 7.1 INTRODUCTION
• 7.2 SEQUENCING TECHNOLOGIES
  • 7.2.1 BULK SEQUENCING (MULTI-CELL SEQUENCING) TECHNOLOGIES
    • 7.2.1.1 Increasing adoption of TCR sequencing for inflammation-mediated diseases to support segment growth
  • 7.2.2 SINGLE-CELL SEQUENCING TECHNOLOGIES
    • 7.2.2.1 Need for integrative analysis of immune receptor repertoires and transcriptional states to spur market growth
• 7.3 LIBRARY PREPARATION TECHNOLOGIES
  • 7.3.1 HIGH DEMAND FOR COST-EFFICIENT AND HIGH-THROUGHPUT IMMUNE REPERTOIRE PROFILING TO FUEL MARKET GROWTH
• 7.4 BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES
  • 7.4.1 GROWING FOCUS ON RESEARCH TO DRIVE DEMAND FOR ADVANCED BIOINFORMATICS & DATA ANALYSIS TECHNOLOGIES

8 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY WORKFLOW

• 8.1 INTRODUCTION
• 8.2 SEQUENCING SERVICES
  • 8.2.1 RISING NEED FOR HIGH-RESOLUTION IMMUNE PROFILING IN CANCER AND AUTOIMMUNE DISEASES TO DRIVE MARKET
• 8.3 DATA ANALYSIS SERVICES
  • 8.3.1 HIGH DEMAND FOR STANDARDIZED NGS DATA INTERPRETATION AND CROSS-SAMPLE COMPARABILITY TO DRIVE MARKET
• 8.4 PRE-SEQUENCING SERVICES
  • 8.4.1 INCREASED REQUIREMENT FOR STANDARDIZED WORKFLOWS FOR ADDRESSING PCR BIAS TO AUGMENT MARKET GROWTH

9 IMMUNE REPERTOIRE SEQUENCING MARKET, BY APPLICATION

• 9.1 INTRODUCTION
• 9.2 RESEARCH APPLICATIONS
  • 9.2.1 LOW SEQUENCING COSTS AND INCREASED NEED TO RESOLVE CELLULAR HETEROGENEITY AT HIGH RESOLUTION TO DRIVE MARKET
• 9.3 DRUG DISCOVERY & DEVELOPMENT
  • 9.3.1 INCREASED NEED FOR TARGETED THERAPIES AND ADVANCEMENTS IN HIGH-THROUGHPUT SCREENING TO AID MARKET GROWTH
• 9.4 CLINICAL DIAGNOSTICS
  • 9.4.1 GROWING DEMAND FOR EARLY DETECTION OF SUBCLINICAL CONDITIONS TO AID MARKET GROWTH

10 IMMUNE REPERTOIRE SEQUENCING PRODUCTS MARKET, BY END USER

• 10.1 INTRODUCTION
• 10.2 ACADEMIC & RESEARCH INSTITUTES
  • 10.2.1 INCREASED FUNDING FOR IMMUNOLOGICAL RESEARCH AND IMMUNOGENOMICS TO DRIVE MARKET
• 10.3 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 10.3.1 RISING FOCUS ON DRUG DISCOVERY AND THERAPEUTIC DEVELOPMENT TO SUPPORT MARKET GROWTH
• 10.4 OTHER END USERS

11 IMMUNE REPERTOIRE SEQUENCING SERVICES MARKET, BY END USER

• 11.1 INTRODUCTION
• 11.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES
  • 11.2.1 NEED TO REDUCE IN-HOUSE INFRASTRUCTURE COSTS AND MEET SCALABILITY DEMANDS TO BOOST MARKET GROWTH
• 11.3 ACADEMIC & RESEARCH INSTITUTES
  • 11.3.1 INCREASING FUNDING FOR GENOMIC RESEARCH AND GROWING DEMAND FOR COMPLEX DATA ANALYSIS TO AID MARKET GROWTH
• 11.4 OTHER END USERS

12 IMMUNE REPERTOIRE SEQUENCING MARKET, BY REGION

• 12.1 INTRODUCTION
• 12.2 NORTH AMERICA
  • 12.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA
  • 12.2.2 US
    • 12.2.2.1 US to dominate North American market during forecast period
  • 12.2.3 CANADA
    • 12.2.3.1 Presence of advanced research facilities and favorable government-funded genomic studies to spur market growth
• 12.3 EUROPE
  • 12.3.1 MACROECONOMIC OUTLOOK FOR EUROPE
  • 12.3.2 GERMANY
    • 12.3.2.1 Technological advancements in RNA sequencing to fuel market growth
  • 12.3.3 UK
    • 12.3.3.1 Increased cross-sector partnerships and advancements in AI tools for large sequencing datasets to boost market growth
  • 12.3.4 FRANCE
    • 12.3.4.1 Public-private collaborations and increased funding for advanced genomic infrastructure to aid market growth
  • 12.3.5 ITALY
    • 12.3.5.1 High investments in genomic research to drive market
  • 12.3.6 SPAIN
    • 12.3.6.1 Increased government investments in precision medicine, genomic medicine, and data science to propel market growth
  • 12.3.7 REST OF EUROPE
• 12.4 ASIA PACIFIC
  • 12.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC
  • 12.4.2 CHINA
    • 12.4.2.1 Rising incidence of chronic diseases and increasing collaborations among industry stakeholders to drive market
  • 12.4.3 JAPAN
    • 12.4.3.1 Increasing research on long-read and biomolecular sequencing to aid market growth
  • 12.4.4 INDIA
    • 12.4.4.1 Advancements in genomic research and focus on industry-academia collaborations to expedite market growth
  • 12.4.5 SOUTH KOREA
    • 12.4.5.1 Favorable government initiatives and investment in sequencing technologies to boost market growth
  • 12.4.6 AUSTRALIA
    • 12.4.6.1 Increased research funding and favorable government initiatives to drive market
  • 12.4.7 REST OF ASIA PACIFIC
• 12.5 LATIN AMERICA
  • 12.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA
  • 12.5.2 BRAZIL
    • 12.5.2.1 Supportive regulatory framework for biotechnology innovation to fuel market growth
  • 12.5.3 MEXICO
    • 12.5.3.1 High geriatric population and advancements in precision medicine research to support market growth
  • 12.5.4 REST OF LATIN AMERICA
• 12.6 MIDDLE EAST
  • 12.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST
  • 12.6.2 GCC COUNTRIES
    • 12.6.2.1 Favorable government initiatives to drive drug development and clinical research
  • 12.6.3 REST OF MIDDLE EAST
• 12.7 AFRICA
  • 12.7.1 RISING GOVERNMENT FUNDING AND INCREASING INTERNATIONAL PARTNERSHIPS TO FAVOR MARKET GROWTH
  • 12.7.2 MACROECONOMIC OUTLOOK FOR AFRICA

13 COMPETITIVE LANDSCAPE

• 13.1 INTRODUCTION
• 13.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2022-2025
• 13.3 REVENUE ANALYSIS, 2022-2024
• 13.4 MARKET SHARE ANALYSIS, 2024
• 13.5 COMPANY VALUATION & FINANCIAL METRICS
  • 13.5.1 COMPANY VALUATION
  • 13.5.2 FINANCIAL METRICS
• 13.6 BRAND/PRODUCT COMPARISON
• 13.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024
  • 13.7.1 STARS
  • 13.7.2 EMERGING LEADERS
  • 13.7.3 PERVASIVE PLAYERS
  • 13.7.4 PARTICIPANTS
  • 13.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024
    • 13.7.5.1 Company footprint
    • 13.7.5.2 Region footprint
    • 13.7.5.3 Product and service footprint
    • 13.7.5.4 Application footprint
• 13.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024
  • 13.8.1 PROGRESSIVE COMPANIES
  • 13.8.2 RESPONSIVE COMPANIES
  • 13.8.3 DYNAMIC COMPANIES
  • 13.8.4 STARTING BLOCKS
  • 13.8.5 COMPETITIVE BENCHMARKING
    • 13.8.5.1 Detailed list of key startups/SMEs
    • 13.8.5.2 Competitive benchmarking of key startups/SMEs
• 13.9 COMPETITIVE SCENARIO
  • 13.9.1 PRODUCT LAUNCHES/APPROVALS/UPGRADES
  • 13.9.2 DEALS
  • 13.9.3 EXPANSIONS

14 COMPANY PROFILES

• 14.1 KEY PLAYERS
  • 14.1.1 ILLUMINA, INC.
    • 14.1.1.1 Business overview
    • 14.1.1.2 Products/Services/Solutions offered
    • 14.1.1.3 Recent developments
      • 14.1.1.3.1 Product launches/approvals/upgrades
      • 14.1.1.3.2 Deals
      • 14.1.1.3.3 Expansions
    • 14.1.1.4 MnM view
      • 14.1.1.4.1 Key strengths
      • 14.1.1.4.2 Strategic choices
      • 14.1.1.4.3 Weaknesses & competitive threats
  • 14.1.2 THERMO FISHER SCIENTIFIC INC.
    • 14.1.2.1 Business overview
    • 14.1.2.2 Products/Services/Solutions offered
    • 14.1.2.3 Recent developments
      • 14.1.2.3.1 Product launches/approvals/upgrades
      • 14.1.2.3.2 Deals
      • 14.1.2.3.3 Expansions
    • 14.1.2.4 MnM view
      • 14.1.2.4.1 Key strengths
      • 14.1.2.4.2 Strategic choices
      • 14.1.2.4.3 Weaknesses & competitive threats
  • 14.1.3 PACBIO
    • 14.1.3.1 Business overview
    • 14.1.3.2 Products/Services/Solutions offered
    • 14.1.3.3 Recent developments
      • 14.1.3.3.1 Product launches/approvals/upgrades
      • 14.1.3.3.2 Deals
      • 14.1.3.3.3 Expansions
    • 14.1.3.4 MnM view
      • 14.1.3.4.1 Key strengths
      • 14.1.3.4.2 Strategic choices
      • 14.1.3.4.3 Weaknesses & competitive threats
  • 14.1.4 OXFORD NANOPORE TECHNOLOGIES PLC
    • 14.1.4.1 Business overview
    • 14.1.4.2 Products/Services/Solutions offered
    • 14.1.4.3 Recent developments
      • 14.1.4.3.1 Product launches/approvals/upgrades
      • 14.1.4.3.2 Deals
    • 14.1.4.4 MnM view
      • 14.1.4.4.1 Key strengths
      • 14.1.4.4.2 Strategic choices
      • 14.1.4.4.3 Weaknesses & competitive threats
  • 14.1.5 10X GENOMICS
    • 14.1.5.1 Business overview
    • 14.1.5.2 Products/Services/Solutions offered
    • 14.1.5.3 Recent developments
      • 14.1.5.3.1 Product launches/approvals/upgrades
    • 14.1.5.4 MnM view
      • 14.1.5.4.1 Key strengths
      • 14.1.5.4.2 Strategic choices
      • 14.1.5.4.3 Weaknesses & competitive threats
  • 14.1.6 QIAGEN
    • 14.1.6.1 Business overview
    • 14.1.6.2 Products/Services/Solutions offered
    • 14.1.6.3 Recent developments
      • 14.1.6.3.1 Product launches/approvals/upgrades
      • 14.1.6.3.2 Deals
      • 14.1.6.3.3 Expansions
  • 14.1.7 AGILENT TECHNOLOGIES
    • 14.1.7.1 Business overview
    • 14.1.7.2 Products/Services/Solutions offered
    • 14.1.7.3 Recent developments
      • 14.1.7.3.1 Deals
      • 14.1.7.3.2 Expansions
  • 14.1.8 DANAHER CORPORATION
    • 14.1.8.1 Business overview
    • 14.1.8.2 Products/Services/Solutions offered
    • 14.1.8.3 Recent developments
      • 14.1.8.3.1 Deals
  • 14.1.9 TAKARA BIO INC.
    • 14.1.9.1 Business overview
    • 14.1.9.2 Products/Services/Solutions offered
    • 14.1.9.3 Recent developments
      • 14.1.9.3.1 Deals
  • 14.1.10 ADAPTIVE BIOTECHNOLOGIES
    • 14.1.10.1 Business overview
    • 14.1.10.2 Products/Services/Solutions offered
  • 14.1.11 BGI GROUP
    • 14.1.11.1 Business overview
    • 14.1.11.2 Products/Services/Solutions offered
    • 14.1.11.3 Recent developments
      • 14.1.11.3.1 Product launches/approvals/upgrades
      • 14.1.11.3.2 Deals
      • 14.1.11.3.3 Other developments
  • 14.1.12 TECAN TRADING AG
    • 14.1.12.1 Business overview
    • 14.1.12.2 Products/Services/Solutions offered
    • 14.1.12.3 Recent developments
      • 14.1.12.3.1 Deals
  • 14.1.13 AZENTA US INC.
    • 14.1.13.1 Business overview
    • 14.1.13.2 Products/Services/Solutions offered
  • 14.1.14 PERSONALIS, INC.
    • 14.1.14.1 Business overview
    • 14.1.14.2 Products/Services/Solutions offered
    • 14.1.14.3 Recent developments
      • 14.1.14.3.1 Deals
      • 14.1.14.3.2 Other developments
  • 14.1.15 CREATIVE BIOLABS
    • 14.1.15.1 Business overview
    • 14.1.15.2 Products/Services/Solutions offered
• 14.2 OTHER PLAYERS
  • 14.2.1 CELEMICS, INC.
  • 14.2.2 CELLCARTA
  • 14.2.3 IREPERTOIRE, INC.
  • 14.2.4 NEW ENGLAND BIOLABS
  • 14.2.5 CERBA RESEARCH
  • 14.2.6 CEGAT GMBH
  • 14.2.7 ELEMENT BIOSCIENCES
  • 14.2.8 SEQALIS
  • 14.2.9 SYNBIO TECHNOLOGIES
  • 14.2.10 MEDGENOME
  • 14.2.11 ENPICOM

15 APPENDIX

• 15.1 DISCUSSION GUIDE
• 15.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 15.3 CUSTOMIZATION OPTIONS
• 15.4 RELATED REPORTS
• 15.5 AUTHOR DETAILS